In a report released today, Steven Halper from Cantor Fitzgerald maintained a Hold rating on Allscripts (MDRX), with a price target of $12. The company’s shares opened today at $9.83, close to its 52-week low of $9.24.
Halper noted:
“MDRX shares continue to have upside to our DCF-based price target of $12. Key assumptions in our model include mid-to-high single-digit revenue growth for the next few years, continued margin improvement, and WACC of 8.15%. While core performance appears to be improving, the EIS acquisition should result in stronger EPS growth, at least in the 2018-2019 time frame. Accordingly, we rate the shares at Overweight.”
According to TipRanks.com, Halper is a top 25 analyst with an average return of 19.5% and a 67.8% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Hms Holdings Corp, and Tivity Health Inc.
Allscripts has an analyst consensus of Moderate Buy, with a price target consensus of $14.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.13 and a one-year low of $9.24. Currently, Allscripts has an average volume of 1.98M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allscripts Healthcare Solutions, Inc. engages in the provision of clinical, financial, connectivity, information solutions, and related professional services. It operates through the following segments: Clinical and Financial Solutions; Population Health; and Netsmart.
